<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01138527</url>
  </required_header>
  <id_info>
    <org_study_id>RU PCa-MAP</org_study_id>
    <nct_id>NCT01138527</nct_id>
  </id_info>
  <brief_title>Prostate Cancer Localization With a Multiparametric Magnetic Resonance (MR) Approach</brief_title>
  <acronym>PCa-MAP</acronym>
  <official_title>Prostate Cancer Localization With a Multiparametric MR Approach</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Siemens AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mount Vernon Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Multi-Imagem and CDPI, Rio de Janeiro, Brasil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Norwegian University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this prospective multi-centre study is to prove the diagnostic
      accuracy of in vivo 3T multi-modality Magnetic Resonance Imaging (high resolution T2-weighted
      MRI, DCE-MRI, MRSI and DWI techniques) in distinguishing carcinoma from other prostate
      tissue. The gold standard for distinguishing the tissue types is the analysis of whole-mount
      sections of the resected prostate by a genitourinary histopathologist.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Goal Proving that multi-parametric MR imaging in a multi-centre setting allows for localizing
      clinically significant (volume &gt; 0.5cc; Gleason &gt; 6) prostate carcinoma in the prostate.

      Objective 1

      To determine the diagnostic accuracy (area under the receiver-operating characteristic curve)
      of 3-Tesla multi-modality non-endorectal coil (ERC) MR imaging in localizing prostate cancer,
      by correlating:

        1. focal areas of low signal intensity on T2-weighted images;

        2. the extent and degree of deviating metabolite ratios derived from MRSI. This can be the
           choline+creatine/citrate ratio or if possible, the choline / citrate ratio;

        3. the extent and degree of apparent diffusion coefficient reduction on DWI;

        4. the extent and degree of perfusion abnormality on DCE-MRI; with the presence or absence
           of cancer at (reconstructed) whole mount section histopathology.

      Objective 2 Proving that multi-modality MR data allows for predicting tumor grade. The
      parameters from the different MR methods for a tumor focus can be correlated to the local
      Gleason grade of the corresponding lesion in the histopathological specimens.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2010</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the ROC curve to distinguish between cancer and non-cancer tissue in the prostate</measure>
    <time_frame>December 2015</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the ROC curve to separate low aggressive from intermediate and high aggressive prostate cancer</measure>
    <time_frame>december 2015</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Biopsy-proven prostate cancer</arm_group_label>
    <description>Patients with biopsy-proven prostate cancer, planned for radical prostatectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MRI examination</intervention_name>
    <description>45-minute MRI examination of the prostate and surrounding tissues with T2-weighted MRI, diffusion-weighted MRI, Spectroscopic Imaging and dynamic contrast enhanced imaging</description>
    <arm_group_label>Biopsy-proven prostate cancer</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      fixed histopathology slides of resected prostates at local institutions: Not different from
      clinical routine
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Biopsy-proven patients with prostate cancer, planned for radical prostatectomy.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy-proven diagnosis of adenocarcinoma of the prostate

          -  Subject will sign a consent form prior to study entry

          -  Radical prostatectomy and histopathological exam planned

          -  The time interval between last biopsy and the MR exam must be at least 4 weeks

          -  The time interval between MR exam and radical prostatectomy should not exceed 12 weeks

        Exclusion Criteria:

          -  Subjects who are unable to give valid informed consent

          -  Subjects who are unwilling or unable to undergo an MR exam, including subjects with
             contra-indications to MR exams

          -  Therapy or surgical procedure applied to the prostate or to other organs in vicinity
             to the prostate: among the therapies preventing inclusion are any form of radiation
             therapy, cryo-therapy, thermal-therapy, therapy based on any other medication
             (including hormonal therapy).

          -  Patients under hormone deprivation therapy.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tom W Scheenen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radiology, Radboud University Nijmegen Medical Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jurgen J FÃ¼tterer, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radiology, Radboud University Nijmegen Medical Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>David Geffen School of Medicine at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Medical Institutions</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University Vienna</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ghent University Hospita</name>
      <address>
        <city>Ghent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Network, Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Mannheim, Heidelberg University</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radboud University Nijmegen Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norwegian University of Science and Technology</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Vernon Hospital, Paul Strickland Scanner Centre</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Brazil</country>
  </removed_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2010</study_first_submitted>
  <study_first_submitted_qc>June 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2010</study_first_posted>
  <last_update_submitted>November 9, 2015</last_update_submitted>
  <last_update_submitted_qc>November 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>multi-parametric MRI approach</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

